Cite
HARVARD Citation
Pan, X. et al. (2022). Epigenome signature as an immunophenotype indicator prompts durable clinical immunotherapy benefits in lung adenocarcinoma. Briefings in bioinformatics. 23 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pan, X. et al. (2022). Epigenome signature as an immunophenotype indicator prompts durable clinical immunotherapy benefits in lung adenocarcinoma. Briefings in bioinformatics. 23 (1), p. . [Online].